On Monday, Lyra Therapeutics Inc (NASDAQ: LYRA) was 3.21% up from the session before settling in for the closing price of $0.19. A 52-week range for LYRA has been $0.16 – $6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 98.14% over the past five years. When this article was written, the company’s average yearly earnings per share was at -5.36%. With a float of $53.69 million, this company’s outstanding shares have now reached $65.46 million.
Let’s look at the performance matrix of the company that is accounted for 88 employees. In terms of profitability, gross margin is -816.72%, operating margin of -6894.43%, and the pretax margin is -6632.36%.
Lyra Therapeutics Inc (LYRA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lyra Therapeutics Inc stocks. The insider ownership of Lyra Therapeutics Inc is 17.98%, while institutional ownership is 46.24%.
Lyra Therapeutics Inc (LYRA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.56% during the next five years compared to -21.63% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
You can see what Lyra Therapeutics Inc (LYRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics Inc (NASDAQ: LYRA) saw its 5-day average volume 1.07 million, a negative change from its year-to-date volume of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 63.17%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 22.21%, which indicates a significant decrease from 60.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.58% in the past 14 days, which was lower than the 91.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1939, while its 200-day Moving Average is $0.4466. Nevertheless, the first resistance level for the watch stands at $0.2004 in the near term. At $0.2077, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.2160. If the price goes on to break the first support level at $0.1848, it is likely to go to the next support level at $0.1765. The third support level lies at $0.1692 if the price breaches the second support level.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
There are 65,458K outstanding shares of the company, which has a market capitalization of 12.63 million. As of now, sales total 1,560 K while income totals -62,680 K. Its latest quarter income was 200 K while its last quarter net income were -11,870 K.
